Corgenix Medical Corp., Genesis Bioventures deal

Anti-phospholipid test developer and manufacturer CONX and diagnostic company GBI will merge in a stock deal. GBI will issue 14 million shares for ownership of CONX, valuing the deal at about $11.2 million based on GBI's closing stock price of $0.80 on March 15. GBI said the merged company will focus on developing GBI's mammastatin breast cancer diagnostic, converting the test to ELISA diagnostic format using CONX's manufacturing process. ...